08.26.24 -- Report: Single-use Bioreactor Uptake Plateaued, Other SUT On The Rise

Examine a new cell culture medium which offers an improved alternative to classical formulations that can help address the constraints in viral vector manufacturing and scale-up.

Rapid development of high-quality cell lines is vital to biomanufacturing projects. How developers approach the fundamental steps can define their core biologics capabilities and keep projects on track.

Transposase-mediated genome engineering enables the robust and stable relocation of discrete DNA segments (transposons) in the genome, providing a valuable tool for stable transgene expression.

Review this demonstration of a bioreactor and bioreactor system combination used to isolate exosomes after culturing human adipose-derived stem cells in suspension on microcarriers.

This demonstration examines an AAV upstream process in proprietary bioreactors, including an example of using process optimization to increase the fraction of full AAV capsids.

Explore the challenges of media screening and a straightforward approach for saving time, reducing risks, and improving outcomes.

As the cell therapy industry experiences rapid growth, media and reagents present a valuable opportunity to meet future therapeutic needs.

Learn about the recirculation and perfusion processes made possible by single-use, fixed-bed bioreactors designed for scaling up adherent cell culture processes.

Review practical considerations for implementing NAT-based methods, where concrete recommendations are necessary, and how guidelines can remain relevant for new medicinal products.

Emulate and Cedars-Sinai Medical Center have partnered to develop a Patient-on-a-Chip program that combines their stem cell expertise and Organs-on-Chips technology to advance precision medicine.

This study compares a serum-free medium to other commercially available pre-hydrated media to measure its effectiveness in supporting the culture of adherent Vero cells.

Discover how to simplify and accelerate CHO-S stable cell line development, eliminating the need for extensive screening of candidate clones and specialized equipment.